National Adoption of WATS3D Accelerates as Cooper University Health Care Physicians Advance Early Detection of Esophageal Disease

August 13, 2025 10:00 AM

The WATS3D test system, an AI-powered diagnostic platform for esophageal disease, continues to gain national traction as Cooper University Health Care Gastroenterologists Anthony Infantolino, MD, FACP, FACG, AGAF, MASGE and Christina Tofani, MD, FACG, FASGE continue to integrate the test into clinical practice. Cooper University Health Care's Division of Gastroenterology is dedicated to providing patients with the most advanced diagnostic and...

Read more

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

August 13, 2025 8:01 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today announced a significant expansion of its intellectual property portfolio for TH-104, its novel transmucosal film. The new patents, recently granted and allowed across key global markets, will enable the Company's...

Read more

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

August 13, 2025 8:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the second quarter 2025.Recent HighlightsExpanded its collaboration with The Scripps Research Institute ("TSRI") to advance the development of the Company's development program evaluating the combination of...

Read more

Aspira Announces Second Quarter 2025 Financial Results and Provides Business Update

August 13, 2025 6:00 AM

Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and six months ended June 30, 2025. The Company also reported early progress under its new leadership team.Second Quarter Highlights:Aspira reported total product revenue of $2.404...

Read more

eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today

August 12, 2025 4:50 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar at 5:00 PM Eastern Time to provides an update on operations through the fiscal quarter that ended June 30, 2025.Michael Heltzen, CEO of eXoZymes, states, "I'm delighted to see our team continue hitting important scientific and business...

Read more

ClearPoint Neuro Reports Second Quarter 2025 Results

August 12, 2025 4:05 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2025.Second Quarter HighlightsReported record quarterly revenue of $9.2 million, a 17% year-over-year increase compared with the second quarter of 2024;Neurosurgery navigation and therapy revenue grew 33% to $3.4...

Read more

Dr. Roy Levitt, Executive Chairman of Adolore BioTherapeutics, Presented at the Next Generation Gene Therapy Vectors Summit

August 12, 2025 1:20 PM

Adolore BioTherapeutics, Inc., ("Company" or "Adolore") announced that Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL UH3 Award supporting ADB-102 development for the treatment of chronic knee pain due to osteoarthritis, ("OA"), and founder and Executive Chairman of Adolore presented the Company's breakthrough non-opioid gene therapy programs for chronic...

Read more

AI Maverick Intel Provides Corporate Update

August 12, 2025 9:25 AM

AI Maverick Intel Inc. (OTCID:BINP), a technology-driven innovator focused on redefining how businesses acquire and engage customers through artificial intelligence, today provided a corporate update. On July 30, 2025, the Company announced its selection of IBN, a leading multi-channel financial news and publishing platform serving both private and public companies, to direct AI Maverick Intel's corporate communications. Earlier today, IBN...

Read more

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

August 12, 2025 9:00 AM

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced promising preclinical results for IGC-M3, a novel small molecule designed to address multiple biological drivers of Alzheimer's disease. IGC-M3 demonstrated activity in laboratory models against beta-amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation, four key contributors to Alzheimer's pathology.The findings underscore IGC...

Read more

InnoSIGN Launches First-in-Class Portal to Identify Disease Drivers from Gene Expression Data

August 12, 2025 9:00 AM

InnoSIGN, a leader in diagnostic-ready computational biology, today announced the launch of the InnoSIGN Portal, a powerful, first-in-class platform designed to uncover the drivers and mechanisms of disease through advanced pathway analysis of RNA sequencing (RNA-seq) data.The secure, cloud-based portal enables researchers, bioinformatics teams, and clinicians to confidentially upload gene expression data and receive quantifiable, interpretable,...

Read more

Lifeloc Reports Second Quarter 2025 Results

August 11, 2025 9:12 AM

Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2025.Second Quarter Financial HighlightsLifeloc posted quarterly net revenue of $2.219 million in the second quarter of 2025, resulting in a quarterly net loss of $(394) thousand, or $(0.14) per diluted share. These results compare to net revenue...

Read more

Publication of Provisional Patent Application for Lenzilumab in Chronic Myelomonocytic Leukemia (CMML)

August 11, 2025 8:00 AM

Taran Therapeutics ("Taran") a privately held company focused on hematology/oncology, and with an almost completely enrolled Phase 2/3 trial with lenzilumab, a monoclonal antibody which neutralizes human granulocyte-macrophage colony-stimulating factor ("GM-CSF") showing benefit in this study in treatment-naïve participants with CMML and RAS-pathway mutations, announced the recent publication of a U.S. Non-Provisional Patent Application. The...

Read more

Biostar Advances Stem Cell Therapy for Autism, Offering New Possibilities for Families

August 8, 2025 12:10 PM

Biostar Stem Cell Technology Research Institute, led by Director Jeong Chan Ra and jointly operated by R BIO and Nature Cell, announced that its regenerative autism treatment has been officially approved by the Japanese Ministry of Health, Labour and Welfare. The approved therapy, which uses autologous fat-derived mesenchymal stem cells, will be offered at Osaka Trinity Clinic, a Biostar-affiliated medical center.With this approval, patients...

Read more

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

August 8, 2025 10:45 AM

Renovaro Inc. (NASDAQ:RENB) was referenced in a recent RealClearDefense article titled "AI Can Be Used to Develop Biological and Chemical Weapons", which examines the complex challenges posed by artificial intelligence in the context of global security and biodefense.The full article can be accessed at: https://www.realcleardefense.com/articles/2025/08/07/ai_can_be_used_to_develop_biological_and_chemical_weapons_1127450.htmlRenovaro's inclusion...

Read more

Faron Pharmaceuticals Ltd: Holding(s) in Company

August 8, 2025 10:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Faron Pharmaceuticals Ltd | Company announcement | August 08, 2025 at 17:00:00 EESTTR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)Non-UK...

Read more

Faron Announces Extension to its Key Patent Family around Bexmarilimab and Targeting Clever-1 in Cancers with a New US Patent Granted

August 8, 2025 3:50 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, today announces that the United States Patent and Trademark Office has granted a new US Patent, No. 12,371,486 for treatment of Clever-1 positive cancers with bexmarilimab and related structures that would bind to Clever-1 molecule for the wanted re-programming effect.The patent is...

Read more

eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST

August 7, 2025 6:35 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025.Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent...

Read more

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

August 7, 2025 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 857,322 special rights entitling to 857,322 existing treasury shares, for an aggregate subscription price of EUR 1,682,067, in connection with an advanced amortisation payment of the First Tranche Bonds (as defined below), which will occur latest on 8 August...

Read more

Therabene Inc. Appoints Dr. Oscar L. Kashala as Chief Medical Officer and Executive Vice President of Global Clinical Development

August 6, 2025 1:30 PM

Therabene Inc., a biotechnology company pioneering next-generation small-molecule protein degraders for the treatment of hard-to-treat cancers, is pleased to announce the appointment of Oscar L. Kashala, MD, PhD, DSc, as Chief Medical Officer and Executive Vice President of Global Clinical Development, effective immediately. Dr. Kashala brings over 30 years of leadership in oncology research, translational medicine, and global...

Read more

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

August 6, 2025 8:30 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announcedpreliminary findings from a VenoValve health economic study, which indicate that the VenoValve would be a cost-effective treatment option for patients with severe Chronic Venous Insufficiency (CVI) caused by deep valvular incompetency. The Company announced it will host a live...

Read more